41 Biotechnology Stocks to Sell Now

41 Biotechnology Stocks to Sell Now

The overall ratings of 41 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Intercept Pharmaceuticals, Inc.’s (ICPT) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

Alexion Pharmaceuticals, Inc. (ALXN) slips from a D to a F this week. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

Celgene Corporation (CELG) is having a tough week. The company’s rating falls from a C to a D. Celgene Corporation is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. For more information, get Portfolio Grader’s complete analysis of CELG stock.

Incyte Corporation (INCY) experiences a ratings drop this week, going from last week’s C to a D. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. The company also gets F’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of INCY stock.

Ultragenyx Pharmaceutical, Inc.’s (RARE) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RARE stock.

Alkermes Plc (ALKS) earns a D this week, moving down from last week’s grade of C. Alkermes Plc is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

This week, Seattle Genetics, Inc. (SGEN) drops from a C to a D rating. Seattle Genetics, Inc. is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Slipping from a C to a D rating, DBV Technologies SA Sponsored ADR (DBVT) takes a hit this week. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of DBVT stock.

ACADIA Pharmaceuticals Inc. (ACAD) gets weaker ratings this week as last week’s C drops to a D. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ACAD stock.

This is a rough week for Cepheid (CPHD). The company’s rating falls to F from the previous week’s D. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company also gets F’s in earnings growth and return on equity. For more information, get Portfolio Grader’s complete analysis of CPHD stock.

Cellectis SA Sponsored ADR (CLLS) declines this week from a C to a D. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

Intrexon Corporation (XON) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of XON stock.

Slipping from a D to a F rating, Portola Pharmaceuticals, Inc. (PTLA) takes a hit this week. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTLA stock.

This week, Enanta Pharmaceuticals, Inc.’s (ENTA) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

Blueprint Medicines Corp. (BPMC) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

Flexion Therapeutics, Inc. (FLXN) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

Adamas Pharmaceuticals, Inc.’s (ADMS) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in sales growth, operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADMS stock.

This is a rough week for Insys Therapeutics, Inc. (INSY). The company’s rating falls to F from the previous week’s D. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth and earnings growth. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Ascendis Pharma A/S Sponsored ADR (ASND) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ASND stock.

This week, OncoMed Pharmaceuticals, Inc. (OMED) drops from a C to a D rating. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Tobira Therapeutics, Inc. (TBRA) slips from a C to a D this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Concert Pharmaceuticals, Inc. (CNCE) declines this week from a D to a F. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

Trillium Therapeutics Inc. (TRIL) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRIL stock.

Pfenex, Inc.’s (PFNX) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Xenon Pharmaceuticals Inc. (XENE) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in sales growth, operating margin growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of XENE stock.

PTC Therapeutics, Inc. (PTCT) slips from a D to a F this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTCT stock.

Aldeyra Therapeutics, Inc. (ALDX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

This is a rough week for OvaScience, Inc. (OVAS). The company’s rating falls to F from the previous week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OVAS stock.

ProQR Therapeutics N.V. (PRQR) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRQR stock.

This week, Strongbridge Biopharma plc’s (SBBP) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of SBBP stock.

This week, Synergy Pharmaceuticals, Inc. (SGYP) drops from a D to a F rating. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGYP stock.

Slipping from a C to a D rating, Stellar Biotechnologies, Inc. (SBOT) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

Regulus Therapeutics Inc. (RGLS) is having a tough week. The company’s rating falls from a D to a F. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Asterias Biotherapeutics Inc Class A (AST) slips from a C to a D this week. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AST stock.

Ohr Pharmaceutical, Inc. (OHRP) experiences a ratings drop this week, going from last week’s B to a D. Ohr Pharmaceutical, Inc. develops pharmaceuticals for wound care and to treat cachexia. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

Cleveland BioLabs, Inc.’s (CBLI) rating weakens this week, dropping to a D versus last week’s C. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from radiation and other stresses. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBLI stock.

Synthetic Biologics, Inc. (SYN) gets weaker ratings this week as last week’s C drops to a D. Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of SYN stock.

This is a rough week for MEI Pharma, Inc. (MEIP). The company’s rating falls to D from the previous week’s C. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

Slipping from a C to a D rating, Catalyst Biosciences, Inc. (CBIO) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBIO stock.

This week, Celsion Corporation (CLSN) drops from a D to a F rating. Celsion Corporation is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLSN stock.

This week, Fibrocell Science, Inc.’s (FCSC) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FCSC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/07/41-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC